Prosecution Insights
Last updated: September 17, 2026
Application No. 17/898,960

PSYCHOLOGICAL FATIGUE PREVENTER OR IMPROVER

Non-Final OA §102
Filed
Aug 30, 2022
Priority
Aug 31, 2021 — JP 2021-141738
Examiner
CHEN, CATHERYNE
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Fujicco Co. Ltd.
OA Round
3 (Non-Final)
37%
Grant Probability
At Risk
3-4
OA Rounds
2m
Est. Remaining
55%
With Interview

Examiner Intelligence

Grants only 37% of cases
37%
Career Allowance Rate
294 granted / 786 resolved
-22.6% vs TC avg
Strong +18% interview lift
Without
With
+18.0%
Interview Lift
resolved cases with interview
Typical timeline
4y 3m
Avg Prosecution
53 currently pending
Career history
840
Total Applications
across all art units

Statute-Specific Performance

§101
14.4%
-25.6% vs TC avg
§103
41.3%
+1.3% vs TC avg
§102
18.4%
-21.6% vs TC avg
§112
19.4%
-20.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 786 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 4/24/2026 has been entered. Claims 1-5 and 7-10 are pending and examined on the merits. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Any rejection not reiterated below are hereby withdrawn. Election/Restrictions Applicant’s election without traverse of the species mental fatigue in the reply filed on Feb. 18, 2025 is acknowledged. Information Disclosure Statement The information disclosure statements (IDS) submitted on 7/7/2026, 5/7/2026, 1/20/23, 5/25/23, 8/23/23, 7/23/2023, 2/14/24, 8/22/24, 3/10/25 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Response to Amendment Claim Rejections - 35 USC § 102 Claim(s) 1-5 and 7-10 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Sakimoto et al. (JP 2005261237 A) as evidenced by Kanamoto et al. (2011, J Agric Food Chem, 59: 8985-8993). This is a new rejection. Sakimoto et al. teaches a method of improving food effective for improving asthenopia with black soybean seed coat extract composition extracted from black soybean seed coat used as the main ingredient for improving eyestrain and stiff shoulders (Abstract, Background Art). Black soybean seed coat extract contains anthocyanin compounds, which are plant pigments, and contains a lot of cyanidin 3-glucoside, which is said to be highly active, and it causes eye fatigue, dry eyes, headache and stiff shoulders. It has the effect of improving eye strain represented by symptoms (Tech Solution, paragraph 3). Headache is a mental stress. Black soybean seed coat extraction solvent at pH 1-5. Acids to be adjusted to pH 1 to 5 include inorganic acids (hydrochloric acid, sulfuric acid, etc.) or organic acids (formic acid, acetic acid, citric acid, ascorbic acid, etc.), and extraction solvents are water (Best-Mode, paragraph 4). The same extraction solvent and ingredient are used in the same way; therefore, the composition would inherently contain the same compounds in the same amounts as in Claim 1. The black soybean seed coat extract contained 9.2% cyanidin-3-glucoside, 6.2% epicatechin, and 39.7% procyanidins that contains 6.1% dimers, 3.4% trimers, 0.5% tetramers (Kanamoto et al., Table 1, left column). The same extract contains the lower concentration of cyanidin-3-glucoside as compared to a total concentration of 2-mer to 9-mer proanthocyanidins (Kanamoto et al., Table 1, right column). Response to Arguments Applicant argues that the reference does not teach any components contained in the black soybean seed coat extract. In response to Applicant’s argument, the new reference teaches black soybean seed coat extract contained 9.2% cyanidin-3-glucoside, 6.2% epicatechin, and 39.7% procyanidins that contains 6.1% dimers, 3.4% trimers, 0.5% tetramers (Kanamoto et al., Table 1, left column). The same extract contains the lower concentration of cyanidin-3-glucoside as compared to a total concentration of 2-mer to 9-mer proanthocyanidins (Kanamoto et al., Table 1, right column). Applicant argues that the extraction processes are not the same. In response to Applicant’s argument, the claims are drawn toward a method of treating a condition with extracting black soybean seed coat with water and sulfuric acid. Black soybean seed coat extraction solvent at pH 1-5. Acids to be adjusted to pH 1 to 5 include inorganic acids (hydrochloric acid, sulfuric acid, etc.) or organic acids (formic acid, acetic acid, citric acid, ascorbic acid, etc.), and extraction solvents are water (Best-Mode, paragraph 4). The same method is taught. Conclusion No claim is allowed. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to CATHERYNE CHEN whose telephone number is (571)272-9947. The examiner can normally be reached on Monday-Friday 9-5:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice . If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand U Desai can be reached on 571-272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Catheryne Chen Examiner Art Unit 1655 /ANAND U DESAI/Supervisory Patent Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Show 2 earlier events
Sep 10, 2025
Response Filed
Jan 09, 2026
Final Rejection mailed — §102
Apr 06, 2026
Response after Non-Final Action
Apr 23, 2026
Applicant Interview (Telephonic)
Apr 24, 2026
Request for Continued Examination
Apr 24, 2026
Examiner Interview Summary
Apr 27, 2026
Response after Non-Final Action
Jul 27, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12697564
Dephosphorylation-controlled extraction of phosphorylatable psychoactive alkaloids
2y 10m to grant Granted Aug 04, 2026
Patent 12673114
COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING IL-2 SURFACE EXPRESSION-EXTRACELLULAR VESICLES AS ACTIVE INGREDIENT
4y 6m to grant Granted Jul 07, 2026
Patent 12622869
LIPID EMULSION FOR PARENTERAL ADMINISTRATION
5y 4m to grant Granted May 12, 2026
Patent 12616707
COMPOSITIONS AND METHODS FOR IMPROVING GUT HEALTH
2y 11m to grant Granted May 05, 2026
Patent 12589184
CLINICAL DRESSING LOADED WITH COFFEE EXTRACT
9m to grant Granted Mar 31, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
37%
Grant Probability
55%
With Interview (+18.0%)
4y 3m (~2m remaining)
Median Time to Grant
High
PTA Risk
Based on 786 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month